A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia.

Breast Cancer Research and Treatment
M E LacoutureS Goldfarb

Abstract

Chemotherapy-induced alopecia (CIA) negatively affects psychosocial health and quality of life (QoL). Currently, there are no approved pharmacologic agents to prevent CIA. Here, we evaluated the safety, tolerability, and potential signal of efficacy of topical calcitriol (BPM31543) on CIA prevention. This Phase 1 trial included 23 female patients with breast cancer, gynecologic cancer, or sarcomas receiving a taxane-based chemotherapy. Patients received a 3 + 3 dose-escalation regimen at 5, 10, 20, 40, 60, and 80 μg/mL, with 3-6 patients per group. Patients applied topical BPM31543 to the scalp twice a day for 2 weeks prior to chemotherapy and continued until chemotherapy treatment was completed. The maximum tolerated dose (MTD) during first 28 day application was determined. Adverse event (AE) monitoring, pharmacokinetics, blinded photographic assessments, and patient self-assessment were evaluated. Out of 23 patients treated with BPM31543, 8 patients experienced at least 1 treatment-related adverse event (AE). The majority of AEs were mild to moderate in severity. Only 1 patient experienced SAEs (vomiting, nausea, fever, and flank pain) considered treatment related. Alopecia < 50% from baseline was observed in 8 patients at W...Continue Reading

References

Feb 20, 2002·The Journal of Investigative Dermatology·Zhongjion XieDaniel D Bikle
Jan 19, 2006·Journal of Cellular Physiology·Daniel D BikleJohn P Sundberg
Sep 15, 2006·Pharmaceutical Research·Jie WangJessie L-S Au
Jun 17, 2008·Molecular Aspects of Medicine·Alex J Brown, Eduardo Slatopolsky
Feb 26, 2010·Kidney International·Annemieke VerstuyfChantal Mathieu
Nov 4, 2010·Current Opinion in Supportive and Palliative Care·Ralph M Trüeb
Jul 18, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Im-Ryung KimJung-Hyun Yang
Sep 3, 2014·Molecular Endocrinology·Thomas S LisseMarie B Demay
Feb 15, 2017·JAMA : the Journal of the American Medical Association·Julie NangiaMothaffar Rimawi
May 26, 2017·JAMA Oncology·Howard Jack West
Mar 13, 2018·Journal of Oncology Practice·Megan Kruse, Jame Abraham

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
M E LacoutureS Goldfarb
International Journal of Cancer. Journal International Du Cancer
Hyoseung ShinSeung-Kwon Myung
International Journal of Dermatology
Belen Rubio-GonzalezNatasha Atanaskova Mesinkovska
Seminars in Cutaneous Medicine and Surgery
Ralph M Trüeb
© 2021 Meta ULC. All rights reserved